The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use has recommended granting marketing authorization for Moderna’s new RNA-based vaccine, mNexspike, for preventing ...

PharmaShell works by covering drug microparticles in a protective film coating made of slow-dissolving material to enhance therapeutic release profile. Credit: Vector_Bird via Shutterstock.com.

Shares of vaccine makers fell Monday after the Food and Drug Administration’s top vaccine regulator said in an internal memo that the agency would introduce stricter vaccine approval rules.

Moderna's narrative is shifting as analysts modestly trim their fair value from $37.32 to $35.78 per share and nudge the discount rate from 7.13% to 7.13%, reflecting a slightly higher required return ...